Radiotherapy in the Management of Cutaneous Melanoma: Effect of Time, Dose, and Fractionation

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

“…Radiation therapy for metastases to the skin, soft tissue, and lymph nodes has also been described in smaller patient groups by 6 further studies [93,413,529,[531][532][533]. Here, cumulative doses of mostly 30 to 40 Gy were employed yielding objective response rates between 45 % and 80 % as well as beneficial palliative effects.…”

“…lungs or liver, has been described in only 5 studies [93,413,414,529,532]. Seegenschmied et al treated 19 pulmonary and 9 hepatic lesions, but they did not break down their findings according to individual sites.…”

“…Systematic search of the literature de-novo: [93,[412][413][414][528][529][530][531][532][533] Strength of consensus: 100 %…”

“…There is a total of 10 case series and retrospective analyses, partly with larger patient groups, on radiation therapy in stage IV melanoma metastases to the skin, subcutis, or lymph nodes [93,[412][413][414][528][529][530][531][532][533]. Frequently, however, the primary study objective was not the efficacy of radiation therapy, but rather the effect of additional measures such as hyperthermia.…”

Lokal rezidiviertes und metastasiertes malignes Melanom Langzeitergebnisse und Prognosefaktoren nach perkutaner Radiotherapie

“…unbekannte Regionen 14 (12%). Die Histologie bei Primärdia-gnose war nodulär (NM) bei 51 (47%), superfiziell spreitend (SSM) bei 35 (25) 3 (27) 17 (30) 10 (19) n. s. Lokalrezidiv (in-field) 2 ( 7) 2 (18) Lokale Lymphknotenmetastase 8 ( 7) 5 ( 9) 3 ( 6) Regionale In-transit-Metastase (M1a) 9 ( 7) 1 ( 9) 6 (11) 2 ( 4) n. s. Fernmetastasen (M1b) 11 ( 9) 6 (11) 5 ( 9) Rezidiv/Progression (Jahre) MW ± SD 2,5 ± 2,1 4,6 ± 3,2 3,3 ± 3,9 0,6 ± 0,8 p < 0,05 Table 4. Initial and long-term response and UICC stage prior to RT start (n. s. = not significant; NED = no evidence of disease).…”